NPPA Updates Draft Pricing Document for Glenmark’s Cardiac Medication Post Review Directive
Following a directive from the Department of Pharmaceuticals (DoP) in October, the National Pharmaceutical Pricing Authority (NPPA) has updated the draft pricing document concerning the retail price of Glenmark Pharmaceuticals’ cardiovascular medication, which combines cilnidipine 20 mg and telmisartan 40 […]